Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features

NCT00462332 is registered in ClinicalTrials.gov with Gruppo Italiano Malattie EMatologiche dell'Adulto as lead sponsor.

NCT NCT00462332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00462332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Pilot Trial to Evaluate the Efficacy of a Combined Therapy Approach for Young CLL Patients With Advanced and Progressive Disease Stratified According to the Biological Prognostic Features
Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
June 30, 2011
Enrollment
86 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia